August 19, 2009 / 4:44 AM / 8 years ago

Glenmark shares slide 17.4 pct on lung drug failure

MUMBAI, Aug 19 (Reuters) - Shares in Indian drugmaker Glenmark Pharmaceuticals (GLEN.BO) fell as much as 17.4 percent on Wednesday to their lowest in more than a month after the company and partner Forest Laboratories FRX.N said their lung drug failed in mid-stage trial. [ID:nSP458535]

    At 0437 GMT, the company’s shares were down 9.4 percent at 237.05 rupees, after falling to as low as 216 rupees.

    The 30-share BSE index .BSESN was up 0.2 percent. (Reporting by Pratish Narayanan)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below